CHICAGO, June 16, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meridian Bioscience (Nasdaq: VIVO), Abbott Laboratories (NYSE: ABT), Becton, Dickinson and Company (NYSE: BDX), Thermo Fisher (NYSE: TMO) and Siemens (NYSE: SI).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
Meridian Tests for Killer E.coli
Diagnostic test kit maker Meridian Bioscience (Nasdaq: VIVO) recently reported that its tests have successfully detected the deadly toxins produced by E. coli O104:H4, the rare strain of the bacterium Escherichia coli (E. coli) responsible for the recent E. coli outbreak in Europe.
E. coli O104:H4, the virulent shiga toxin producing E. coli ("STEC") strain, is responsible for many deaths and has also caused hemolytic uremic syndrome ("HUS") in hundreds of others. HUS, which predominantly affects children, is a life-threatening condition which typically occurs when an infection in the digestive system produces toxic substances that destroy red blood cells, leading to kidney failure.
STEC, the common foodborne contaminants, is the shiga toxins (shiga toxin 1 or shiga toxin 2) that the organisms produce, causing serious complications in the infected person. Studies reveal that shiga toxin 2 has a higher association with HUS. As such, rapid detection of toxin 2 type will allow physicians to immediately isolate and treat infected patients to lower the chances of HUS development.
Europe has been plagued by the worst E. coli crisis in recent history. Already 37 people have reportedly succumbed to Germany's killer E. coli outbreak, the one of its kind ever recorded.
There has been 1 confirmed and three suspected cases of E. coli O104:H4 infection in the U.S. Moreover, 1 HUS case in Massachusetts has been confirmed as similar to the German outbreak strain.
Meridian conducted testing on one of these clinical samples using its two distinct tests for STEC (Premier EHEC and ImmunoCard STAT! EHEC) and confirmed that its tests have correctly identified the samples as shiga toxin 2 producing. The Premier EHEC and ImmunoCard STAT! EHEC tests detected both shiga toxin types. The ImmunoCard STAT! EHEC offers an added benefit as it differentiates between shiga toxin 1 and shiga toxin 2.
Cincinnati-based Meridian specializes in developing diagnostic test kits for multiple serious and infectious diseases. Its diagnostics business faces strong competition from Abbott Laboratories (NYSE: ABT), Becton, Dickinson and Company (NYSE: BDX), Thermo Fisher (NYSE: TMO) and Siemens (NYSE: SI).
Meridian is expecting a rebound in 2011 from a beleaguered fiscal 2010 which was hit by a dreary influenza season, stiff competition in its C. difficile diagnostic business and a soft economy.
The company hopes sales in fiscal 2011 to be boosted by its diagnostic test kits for detecting bacteria like C. difficile and H. pylori. Moreover, the illumigene molecular test platform, which represents Meridian's response to growing competition, is expected to be its principal growth engine in the coming years.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
Share this article